Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence

Bibliography

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167–78
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306–14
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574–9
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care 2002;8(19 Suppl):S616–30
   Google Scholar
• Sacco E, Tienforti D, D'Addessi A, et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Res Rep Urol 2010;2:11–24
   Google Scholar
• Andersson KE, Chapple CR, Cardozo L. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors, Incontinence, 4th international consultation on incontinence. Plymouth, Plymbridge Distributors Ltd, Plymouth, UK; 2009. p. 631–99
   Google Scholar
• Sacco E. Physiopathology of overactive bladder syndrome. Urologia 2012;79(1):24–35
   PubMedGoogle Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):543–62
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110(11):1767–74
   PubMed Web of Science ®Google Scholar
• Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(4):583–98
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014;33(1):17–30
   PubMed Web of Science ®Google Scholar
• Arch JR, Ainsworth AT, Cawthorne MA, et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984;309(5964):163–5
   PubMed Web of Science ®Google Scholar
• Strosberg AD. Structure and function of the beta3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997;37:421–50
   PubMed Web of Science ®Google Scholar
• Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989;8:245(4922):1118–21
   Google Scholar
• Ursino MG, Vasina V, Raschi E, et al. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59(4):221–34
   PubMed Web of Science ®Google Scholar
• Arch JR, Wilson S. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes Relat Metab Disord 1996;20(3):191–9
   PubMed Web of Science ®Google Scholar
• Mathvink RJ, Tolman JS, Chitty D, et al. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. J Med Chem 2000;43(21):3832–6
   PubMed Web of Science ®Google Scholar
• Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119
   PubMed Web of Science ®Google Scholar
• Nergårdh A, Boréus LO, Naglo AS. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol (Copenh) 1977;40(1):14–21
   PubMedGoogle Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126(3):819–25
   PubMed Web of Science ®Google Scholar
• Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999;288(3):1367–73
   PubMed Web of Science ®Google Scholar
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170(2 Pt 1):649–53
   PubMed Web of Science ®Google Scholar
• Badawi JK, Uecelehan H, Hatzinger M, et al. Relaxant effects of beta-adrenergic agonists on porcine and human detrusor muscle. Acta Physiol Scand 2005;185:151–9
   PubMedGoogle Scholar
• Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3- adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 2006;98:1310–14
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473–81
   PubMed Web of Science ®Google Scholar
• Longhurst PA, Levendusky M. Pharmacological characterization of betaadrenoceptors mediating relaxation of the rat urinary bladder in vitro. Br J Pharmacol 1999;127:1744–50
   PubMed Web of Science ®Google Scholar
• Igawa Y and Michel MC. Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 2013;386(3):177–83
   PubMed Web of Science ®Google Scholar
• Michel MC, Sand C. Effect of pre-contraction on beta-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 2009;27:711–15
   PubMed Web of Science ®Google Scholar
• Woods M, Carson N, Norton NW, et al. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001;166:1142–7
   PubMed Web of Science ®Google Scholar
• Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168(3):1247
   PubMed Web of Science ®Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (Solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007;323(1):202–9
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321(2):642–7
   PubMed Web of Science ®Google Scholar
• Takeda H, Yamazaki Y, Igawa Y, et al. Effects of beta3-adrenoceptor stimulation on prostaglandin E2-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 2002;21:558–65
   PubMed Web of Science ®Google Scholar
• Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta3-adrenergic receptor agonist CL-316243 on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326(1):178–85
   PubMed Web of Science ®Google Scholar
• Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010;29:771–6
   PubMed Web of Science ®Google Scholar
• Murakami S, Chapple CR, Akino H, et al. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int 2007;99:669–73
   PubMed Web of Science ®Google Scholar
• Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998;275:F226–9
   PubMed Web of Science ®Google Scholar
• Kanai A, Wyndaele JJ, Andersson KE, et al. Researching bladder afferents determining the effects of b3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn 2011;30:684–91
   PubMed Web of Science ®Google Scholar
• Vrydag W, Alewijnse AE, Michel MC. Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? Br J Pharmacol 2009;156:127–34
   PubMed Web of Science ®Google Scholar
• Honda K, Yamaguchi O, Nomiya M, et al. Association between polymorphism of beta3-adrenoceptor gene and overactive bladder. Neurourol Urodyn 2013; published online 29 Aug 2013; doi: 10.1002/nau.22476
   Web of Science ®Google Scholar
• Perrone MG, Santandrea E, Bleve L, et al. Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists. Bioorg Med Chem 2008;16(5):2473–88
   PubMed Web of Science ®Google Scholar
• Maruyama T, Onda K, Hayakawa M, et al. Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists. Eur J Med Chem 2009;44(6):2533–43
   PubMed Web of Science ®Google Scholar
• Weber AE, Mathvink RJ, Perkins L, et al. Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor. Bioorg Med Chem Lett 1998;8(9):1101–6
   PubMed Web of Science ®Google Scholar
• Parmee ER, Ok HO, Candelore MR, et al. Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. Bioorg Med Chem Lett 1998;8(9):1107–12
   PubMed Web of Science ®Google Scholar
• Maruyama T, Onda K, Hayakawa M, et al. Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists. Chem Pharm Bull (Tokyo) 2010;58(4):533–45
   PubMed Web of Science ®Google Scholar
• Hu B, Jennings LL. Orally bioavailable beta-2, -3-adrenergic agonists as potential therapeutic agents for obesity and type II diabetes. In: King FD, Oxford AW, editors, Progress in medicinal chemistry. Volume 41. Elsevier Science B V, Amsterdam; 2003. p. 167–94
   Google Scholar
• Maruyama T, Suzuki T, Onda K, et al. Amide derivatives or salts thereof. US6346532B1; 2002
   Google Scholar
• Takasu T, Sato S, Ukai M, Maruyama T. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient. US7750029B2; 2003
   Google Scholar
• Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol 2012;4(6):315–24
   PubMedGoogle Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of a selective beta3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol 2013;386(3):247–53
   PubMed Web of Science ®Google Scholar
• Svalø J, Nordling J, Bouchelouche K, et al. The novel beta3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol 2013;699(1-3):101–5
   PubMed Web of Science ®Google Scholar
• Nantel F, Bouvier M, Strosberg AD, Marullo S. Functional effects of long-term activation on human beta2-and beta3-adrenoceptor signalling. Br J Pharmacol 1995;114:1045–51
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol 2013;386(1):71–8
   PubMed Web of Science ®Google Scholar
• Takeda H, Yamazaki Y, Akahane M, et al. Role of the beta3-adrenoceptor in urine storage in the rat: comparison between the selective beta3-adrenoceptor agonist, CL316,243, and various smooth muscle relaxants. J Pharmacol Exp Ther 2000;293:939–45
   PubMed Web of Science ®Google Scholar
• Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta3-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 2012;110:E132–42
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. Pharmacological profile of the selective beta3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn Schmiedebergs Arch Pharmacol 2013;386(11):1001–8
   PubMed Web of Science ®Google Scholar
• Sawada N, Nomiya M, Hood B, et al. Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol 2013;64(4):664–71
   PubMed Web of Science ®Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on the primary bladder afferent activity and bladder microcontractions in rats in comparison with those of oxybutynin. Eur Urol 2012;62:1166–73
   Google Scholar
• Pharmacology/toxicology review. FDA/Division of Reproductive and Urologic Products Center for Drug Evaluation and Research/Center for Drug Evaluation and Research, 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000PharmR.pdf [Last accessed 12 December 2013]
   Google Scholar
• Astellas Pharma US, Inc. Prescribing information of Mirbetriq. Available from: http://www.us.astellas.com/docs/Myrbetriq_WPI.pdf [Last accessed 12 December 2013]
   Google Scholar
• Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron. FDA/Division of Reproductive and Urologic Products/Office of New Drugs Center for Drug Evaluation and Research, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM298284.pdf [Last accessed 12 December 2013]
   Google Scholar
• Betmiga assessment report. EMA/Committee for Medicinal Products for Human Use (CHMP), 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002388/WC500137308.pdf [Last accessed 10 November 2013]
   Google Scholar
• Available from: www.clinicaltrial.gov Trial identifier: NCT00527033 [Last accessed 12 December 2013]
   Google Scholar
• Available from: www.clinicaltrial.gov Trial identifier: NCT00966004 [Last accessed 12 December 2013]
   Google Scholar
• Available from: www.clinicaltrial.gov Trial identifier: NCT00840645 [Last accessed 12 December 2013]
   Google Scholar
• Chapple CR, Amarenco G, López Aramburu MA, et al.; on behalf of the BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32(8):1116–22
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24(9):1447–58
   PubMed Web of Science ®Google Scholar
• Nitti V, Rosenberg S, Mitcheson HD, et al. Urodynamics and safety of the beta3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190(4):1320–7
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo J, et al. Efficacy and tolerability of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised european–australian phase 3 trial. Eur Urol 2013;63:283–95
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189(4):1388–95
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta-3 adrenoceptor agonist, mirabegron in patients with symptoms of overactive bladder. Urology 2013;82(2):313–20
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63(2):296–305
   PubMed Web of Science ®Google Scholar
• Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 2012;40(4):815–24
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two Phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 2012;34(10):2144–60
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 2012;42(10):957–67
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, Dickinson J, Schaddelee M, et al. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet 2013; published online 1 Jun 2013, doi: 10.1007/s13318-013-0133-1
   PubMed Web of Science ®Google Scholar
• Lee J, Moy S, Meijer J, et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig 2013;33(6):429–40
   PubMed Web of Science ®Google Scholar
• van Gelderen E, Li Q, Meijer J, et al. An exploratory comparison of the single dose pharmacokinetics of the beta 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 2009;85(Suppl 1):S88
   Google Scholar
• Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig 2012;33(1):11–23
   Web of Science ®Google Scholar
• Sawamoto T, Lee J, Alak A, et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 2011;89:S21
   Google Scholar
• Sawamoto T, Lee J, Cao Y, et al. Phase I, open-label, drug interaction study to evaluate the effect of repeat doses of rifampin on the single-dose pharmacokinetics of mirabegron (YM178) in healthy adult subjects. Clin Pharmacol Ther 2011;89:S21
   Google Scholar
• Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 2012;42(12):1187–96
   PubMed Web of Science ®Google Scholar
• Angulo JC, Khullar V, Nitti VW, Siddiqui E. Evidence available on the use of the selective beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder. Actas Urol Esp 2013;37(10):640–51
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67(7):619–32
   PubMed Web of Science ®Google Scholar
• Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol 2013;13(1):45
   PubMedGoogle Scholar
• Khullar V, Cambronero J, Angulo J, et al. Age-related efficacy of the selective beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged ≥ 65 years [Poster 331]. Presented at 42nd ICS meeting; 15 – 19 October 2012; Beijing, China. Available from: http://www.ics.org/Abstracts/Publish/134/000331.pdf [Last accessed 12 December 2013]
   Google Scholar
• Novack GD, Lewis RA, Vogel R, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther 2013;29(7):674–80
   PubMed Web of Science ®Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther 2012;92(6):696–706
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R. Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: an up-to-dated review. World J Obstet Gynecol 2013;2(4):1–9
   Google Scholar
• Cardozo L, Hessdörfer E, Milani R, et al.; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102(9):1120–7
   PubMed Web of Science ®Google Scholar
• Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73(1):14–18
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276–82
   PubMed Web of Science ®Google Scholar
• Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009;65:309–14
   PubMed Web of Science ®Google Scholar
• Novara G, Cornu JN. Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. Eur Urol 2013;63(2):306–8
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrial.gov Trial identifier: NCT01638000 [Last accessed 12 November 2013]
   Google Scholar
• Rekik M, Rouget C, Palea S, et al. Effects of combining antimuscarinics and beta3-adrenoceptor agonists on contractions induced by electrical field stimulation of rat isolated urinary bladder strips. Eur Urol Suppl 2013;12:e440
   Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy results from a phase 2 study (Symphony). J Urol Suppl 2013;189(4S):e803
   Google Scholar
• Available from: www.clinicaltrial.gov Trial identifier: NCT01745094 [Last accessed 12 November 2013]
   Google Scholar
• Athanaspoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011;60:94–105
   PubMed Web of Science ®Google Scholar
• Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a beta(3)-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 2012;50(11):838–50
   PubMed Web of Science ®Google Scholar